These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

504 related items for PubMed ID: 33314735

  • 1. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
    Kim B, Park YS, Sung JS, Lee JW, Lee SB, Kim YH.
    Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
    [Abstract] [Full Text] [Related]

  • 2. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J, You L, Yao J, Xie J, Jing J, Jing Z, Jiang L, Sui X, Pan H, Han W.
    Cancer Lett; 2016 Aug 28; 379(1):124-33. PubMed ID: 27264264
    [Abstract] [Full Text] [Related]

  • 3. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y, Wu J, Yan H, Cheng Y, Wang Y, Yang Y, Deng M, Che X, Hou K, Qu X, Zou D, Liu Y, Zhang Y, Hu X.
    Pharmacol Res; 2020 Sep 28; 159():105007. PubMed ID: 32561477
    [Abstract] [Full Text] [Related]

  • 4. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A, Cao W, Liu X, Zhang Y, Ma Y, Xu R, Zhang R, Liu X, Zhou S, Wang R, Liu J, Tang X.
    J Cancer Res Clin Oncol; 2020 Jul 28; 146(7):1737-1749. PubMed ID: 32342201
    [Abstract] [Full Text] [Related]

  • 5. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, Liu P, Wang Y, Zhang X.
    Theranostics; 2021 Jul 28; 11(2):824-840. PubMed ID: 33391507
    [Abstract] [Full Text] [Related]

  • 6. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y, Yao K, Shi C, Jiang Y, Liu K, Zhao S, Chen H, Reddy K, Zhang C, Chang X, Ryu J, Bode AM, Dong Z, Dong Z.
    Oncotarget; 2015 Dec 29; 6(42):44274-88. PubMed ID: 26517520
    [Abstract] [Full Text] [Related]

  • 7. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway.
    Wang H, Du X, Liu W, Zhang C, Li Y, Hou J, Yu Y, Li G, Wang Q.
    Respir Res; 2024 May 20; 25(1):215. PubMed ID: 38764025
    [Abstract] [Full Text] [Related]

  • 8. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
    Wang F, Meng F, Wong SCC, Cho WCS, Yang S, Chan LWC.
    Ther Adv Respir Dis; 2020 May 20; 14():1753466620915156. PubMed ID: 32552611
    [Abstract] [Full Text] [Related]

  • 9. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.
    BMC Med; 2012 Mar 21; 10():28. PubMed ID: 22436374
    [Abstract] [Full Text] [Related]

  • 10. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H, Li Y, Yuan Y, Li W, Zhang H, Zhang Z, Shi R, Liu M, Liu C, Chen C, Liu H, Chen J.
    BMC Cancer; 2020 Dec 04; 20(1):1189. PubMed ID: 33276757
    [Abstract] [Full Text] [Related]

  • 11. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, Chen HW, Yang PC.
    PLoS One; 2011 Dec 04; 6(8):e23756. PubMed ID: 21858220
    [Abstract] [Full Text] [Related]

  • 12. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S, Im JH, Kim WK, Choi YJ, Lee JY, Kim SK, Kim SJ, Kwon SW, Kang KW.
    Oxid Med Cell Longev; 2021 Dec 04; 2021():5428364. PubMed ID: 34367462
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y, Wu X, Yin Y, Yang Y, Ma D, Li H.
    J Exp Clin Cancer Res; 2014 Jun 17; 33(1):52. PubMed ID: 24939055
    [Abstract] [Full Text] [Related]

  • 14. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F, Zhu T, Cao B, Wang J, Liang L.
    Eur J Cancer; 2017 Oct 17; 84():184-192. PubMed ID: 28822888
    [Abstract] [Full Text] [Related]

  • 15. TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.
    Shuai S, Liao X, Wang H, Liu L, Mei S, Cao J, Wang S.
    Cancer Sci; 2021 Oct 17; 112(10):4139-4150. PubMed ID: 34058054
    [Abstract] [Full Text] [Related]

  • 16. Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway.
    Xie YJ, Gao WN, Wu QB, Yao XJ, Jiang ZB, Wang YW, Wang WJ, Li W, Hussain S, Liu L, Leung EL, Fan XX.
    Pharmacol Res; 2020 Sep 17; 159():104934. PubMed ID: 32464330
    [Abstract] [Full Text] [Related]

  • 17. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
    Kim D, Bach DH, Fan YH, Luu TT, Hong JY, Park HJ, Lee SK.
    Cell Death Dis; 2019 May 01; 10(5):361. PubMed ID: 31043587
    [Abstract] [Full Text] [Related]

  • 18. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
    Chen P, Huang HP, Wang Y, Jin J, Long WG, Chen K, Zhao XH, Chen CG, Li J.
    J Exp Clin Cancer Res; 2019 Jun 13; 38(1):254. PubMed ID: 31196210
    [Abstract] [Full Text] [Related]

  • 19. TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription.
    Yuan W, Xu W, Li Y, Jiang W, Li Y, Huang Q, Chen B, Wu S, Wang Y, Song W, Zhao W, Wu J.
    Cell Death Dis; 2019 Mar 25; 10(4):283. PubMed ID: 30911072
    [Abstract] [Full Text] [Related]

  • 20. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.
    Target Oncol; 2015 Jun 25; 10(2):235-45. PubMed ID: 25077897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.